1-20 of 42
Kate Sasser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Comprehensive Whole Genome Sequencing Assay Provides Robust Characterization of Clinically Relevant Genomic Alterations across Myeloid Malignancies Concordant with Matched Results from Targeted DNA, Whole Transcriptome RNA and Cytogenetic Profiling

Robert Huether, Derick Hoskinson, Pavana Anur, Raul Torres, Karl R Beutner, Yan Yang, Kristiyana Kaneva, Kelly A Potts, Andrew Frazier, Iris Braunstein, Brett Mahon, Michael A Thompson, Kate Sasser, Halla Nimeiri, Lewis J Kraft, Francisco M De La Vega, Shira N. Dinner, Guillermo Garcia-Manero
Journal: Blood
Blood (2024) 144 (Supplement 1): 7481.
https://doi.org/10.1182/blood-2024-199194
Published: 2024
Journal Articles

Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides

Omar Jabado, Christopher Chiu, Matthew Loya, Manling Ma-Edmonds, David Soong, Anantharaman Muthuswamy, Mahesh Bachu, Nicole Bottrel, Han Si, Jimin Zhang, Monica Wielgos-Bonvallet, Julie Blædel, Erin Henitz, Brandon Higgs, Kate Sasser, Suzana Couto, Maria Jure-Kunkel, Mark Fereshteh
Journal: Blood
Blood (2022) 140 (Supplement 1): 6424–6425.
https://doi.org/10.1182/blood-2022-159384
Published: 2022
Journal Articles

Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30 + Hematologic Malignancies

Simone C. Oostindie, Mir Farshid Alemdehy, Maarten L. Janmaat, Jenny M. Meerding, Kristel Kemper, Patrick J. Engelberts, Bart E.C.G. De Goeij, David Satijn, A. Kate Sasser, Esther C.W. Breij
Journal: Blood
Blood (2022) 140 (Supplement 1): 3153–3154.
https://doi.org/10.1182/blood-2022-159396
Published: 2022
Journal Articles

Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial

Jordan Blum, Gregg Masters, Christopher Chiu, Han Si, Jeremy Gale, Lisa Grimm, Manling Ma-Edmonds, Matthew Loya, Mahesh Bachu, Omar Jabado, David Soong, Jimin Zhang, Monica Wielgos-Bonvallet, Nicole Bottrel, Erin Henitz, Brandon Higgs, Kate Sasser, Maria Jure-Kunkel, Mark Fereshteh
Journal: Blood
Blood (2022) 140 (Supplement 1): 6453–6454.
https://doi.org/10.1182/blood-2022-167189
Published: 2022
Journal Articles

Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Andrew Spencer, Katrine Fladeland Iversen, Binod Dhakal, Maria Creignou, Jenny Chen, Ida H Hiemstra, Sieto Bosgra, Avani Badani, Esther C.W. Breij, Lauren K. Brady, A. Kate Sasser, Anders Malmberg, Henrik Gregersen, Markus Hansson, Annemiek Broijl, Maria-Victoria Mateos, Torben Plesner
Journal: Blood
Blood (2022) 140 (Supplement 1): 7320–7321.
https://doi.org/10.1182/blood-2022-159116
Published: 2022
Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-140313
Published: 2020
Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn
Journal: Blood
Blood (2019) 134 (Supplement_1): 3106.
https://doi.org/10.1182/blood-2019-125788
Published: 2019
Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4170.
https://doi.org/10.1182/blood-2018-99-114723
Published: 2018
Journal Articles

Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression

Tineke Casneuf, Volha Tryputsen, Homer Adams, III, Andrew Lysaght, A. Kate Sasser, Robert A Kyle, MD, S. Vincent Rajkumar, MD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3805.
https://doi.org/10.1182/blood.V130.Suppl_1.3805.3805
Published: 2017
Journal Articles

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Serika Naicker, BSc, PhD, Athina Rigalou, BSc MSc, Cian McEllistrim, MB, BCh, BAO, Alessandro Natoni, PhD, Christopher Chiu, Kate Sasser, PhD, Aideen Ryan, BSc,PhD, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 121.
https://doi.org/10.1182/blood.V130.Suppl_1.121.121
Published: 2017
Journal Articles

Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

Maria-Victoria Mateos, MD PhD, Jane Estell, B.MD(Honours), FRACP, FRCPA, Wolney Barreto, PhD, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Ajay Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 1150.
https://doi.org/10.1182/blood.V128.22.1150.1150
Published: 2016
Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1151.
https://doi.org/10.1182/blood.V128.22.1151.1151
Published: 2016
Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3313.
https://doi.org/10.1182/blood.V128.22.3313.3313
Published: 2016
Journal Articles

Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment

Alexander Babich, Yingzhe Li, Francois Gaudet, Fei Huang, Kate Sasser, Mark Salvati, Anna Kalota
Journal: Blood
Blood (2016) 128 (22): 5215.
https://doi.org/10.1182/blood.V128.22.5215.5215
Published: 2016
Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 246.
https://doi.org/10.1182/blood.V128.22.246.246
Published: 2016
Journal Articles

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

Adam Lamble, MD, Yoko Kosaka, PhD, Fei Huang, A Kate Sasser, PhD, Homer Adams, III, PhD, Cristina E. Tognon, Ted Laderas, PhD, Shannon K. McWeeney, Marc M. Loriaux, Jeffrey W. Tyner, Brian J. Druker, MD, Evan F. Lind, PhD
Journal: Blood
Blood (2016) 128 (22): 2829.
https://doi.org/10.1182/blood.V128.22.2829.2829
Published: 2016
Journal Articles

Ex Vivo Activity Profile of the CD123xCD3 Duobody® Antibody JNJ-63709178 Against Primary Acute Myeloid Leukemia Bone Marrow Samples

Ann Forslund, Khaja Syed, Amy Axel, Ronan McDaid, Yingzhe Li, Juan Ballesteros, Francois Gaudet, Ricardo M. Attar, Mark Salvati, Fei Huang, Kate Sasser
Journal: Blood
Blood (2016) 128 (22): 2875.
https://doi.org/10.1182/blood.V128.22.2875.2875
Published: 2016
Journal Articles

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP

Athina Rigalou, MSc., Aideen Ryan, PhD, Alessandro Natoni, PhD, Christopher Chiu, PhD, Kate Sasser, PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2016) 128 (22): 2101.
https://doi.org/10.1182/blood.V128.22.2101.2101
Published: 2016
Journal Articles

Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab

Helene Caillon, PharmD, Alix Irimia, Residential student, Jason S. Simon, PhD, Amy Axel, Kate Sasser, Matthew James Scullion, PhD BSc, Thierry Ligneel, PhD, Georges Nouadje, PhD, Philippe Moreau, Thomas Dejoie, PharmD
Journal: Blood
Blood (2016) 128 (22): 2063.
https://doi.org/10.1182/blood.V128.22.2063.2063
Published: 2016
Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser
Journal: Blood
Blood (2016) 128 (22): 4521.
https://doi.org/10.1182/blood.V128.22.4521.4521
Published: 2016